SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) announced today that in collaboration with a prominent pharmaceutical company, the Genome Institute of Singapore (GIS) will utilize the HumanRef-8 Expression BeadChip to analyze up to 3,000 samples. The GIS is a flagship facility in Singapore that pursues the integration of technology, genetics and biology towards the goal of individualized medicine.
